NCT04826744|Recruiting
Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
PAUPIAD
Loading search results
PAUPIAD
Sponsor study identifier
Secondary identifiers
OTHER · ID-RCB number,ANSM
observational
550
1 country
2
Study Start
September 1, 2021
Actual (reported)Primary Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Atopic dermatitis is a common inflammatory skin disease, resulting from genetical, immunological and environmental factors. Head and neck are among the most frequent involved areas, almost 50% in adult patients according to most publications. Palpebral involvement is also common and a source of major quality of life impairment for patients. However, the real frequency of this palpebral involvement is unknown, only estimated about 20% in few studies. The treatment of this location remains difficult, regarding to the thickness of palpebral skin and proximity of the eye. To our knowledge, no prospective studies about allergological skin tests (such as patch-tests) in atopic patients with palpebral involvement had been conducted. Finally, atopic dermatitis is frequently associated with ophthalmological diseases such as conjunctivitis, keratoconus or cataract, which belong to the minor criteria of Hanifin and Rakja classification. A better knowledge of the atopic dermatitis palpebral involvement and the associated factors seems to be needed to improve the treatment and the quality of life of patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 16, 2021
Actual (reported)April 1, 2021
Actual (reported)September 1, 2021
Actual (reported)June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Ratio of palpebral involvement in adult atopic dermatitis patients, regardless the severity of the disease
At Baseline, the initial consultation of dermatology
Clinical description of the palpebral involvement : acute eczema or chronic eczema
At Baseline, the initial consultation of dermatology
Potential factors associated with palpebral involvement of the atopic dermatitis (socio-demographics factors, clinical factors, comorbidities, treatment, severity …)
At Baseline, (the initial consultation of dermatology ) and at 3 months during the consultation of allergology
Rate of relevant contact sensitization according to the skin testing and the clinical manifestations
At 3 months, at the time of the reading of the tests either at 48 hours and 72 hours
Description of the sensitization profile
At 3 months, at the time of the reading of the tests either at 48 hours and 72 hours
Association between allergic sensitization and severity of the atopic dermatitis
At 3 months, at the time of the reading of the tests either at 48 hours and 72 hours
with clinical examination, score filling such as SCORAD and DLQI * Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history * Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72. * ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients with atopic dermatitis. Systematic inclusion of out-patients and in-patients of the University Hospital of Lille and Rouen, but also patients from liberal physicians (dermatologists and allergists) in Lille and Rouen
Hop Claude Huriez Chu Lille
Lille, 59037, France
Hopital Charles Nicolle Chu Rouen
Rouen, France
Delphine Staumont-Salle, MD,PhD
University Hospital, Lille
First Submitted
March 16, 2021
First Posted
April 1, 2021
Study Start
September 1, 2021
Actual (reported)Primary Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis
Contact the study team to confirm eligibility.
Study Completion
June 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 23, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: